ArticleJournal of nanobiotechnology2021
Rapidly liver-clearable rare-earth core-shell nanoprobe for dual-modal breast cancer imaging in the second near-infrared window.
Article in Journal of nanobiotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Surface bioengineering of lanthanide nanoparticles for theranostic applications: From hydrophilic modification to multimodal imaging and therapy.Materials today. Bio · 2026Review
- Disphosphate based hydrogel microspheres for targeted transarterial radioembolization and chemoembolization therapies.Journal of advanced research · 2026Article
- Application of NIR Fluorescent Materials in Imaging and Treatment of Tumors of Different Depths.Nanomaterials (Basel, Switzerland) · 2025Review
- Inhibiting concentration quenching in YbNature communications · 2025Article
- Clinical applications of nanoprobes of high-resolutioniScience · 2025Review
- Engineered upconversion nanoparticles for breast cancer theranostics.Theranostics · 2025Review
- Application of Intelligent Response Fluorescent Probe in Breast Cancer.Molecules (Basel, Switzerland) · 2024Review
- Tungsten-based nanoparticles as contrast agents for liver tumor detection using dual-energy computed tomography.Biomaterials science · 2023Article
- Intraoperative diagnosis of early lymphatic metastasis using neodymium-based rare-earth NIR-II fluorescence nanoprobe.Nanoscale advances · 2023Article
- Dual-stimuli responsive smart nanoprobe for precise diagnosis and synergistic multi-modalities therapy of superficial squamous cell carcinoma.Journal of nanobiotechnology · 2023Article
- Research Progress on Dual-Modal Fluorescence-MRI Molecular Imaging of Molecular Probes in Breast Cancer.Technology in cancer research & treatmentReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundFluorescence imaging as the beacon for optical navigation has wildly developed in preclinical studies due to its prominent advantages, including noninvasiveness and superior temporal resolution. However, the traditional optical methods based on ultraviolet (UV, 200-400 nm) and visible light (Vis, 400-650 nm) limited by their low penetration, signal-to-noise ratio, and high background auto-fluorescence interference. Therefore, the development of near-infrared-II (NIR-II 1000-1700 nm) nanoprobe attracted significant attentions toward in vivo imaging. Regrettably, most of the NIR-II fluorescence probes, especially for inorganic NPs, were hardly excreted from the reticuloendothelial system (RES), yielding the anonymous long-term circulatory safety issue.
resultsHere, we develop a facile strategy for the fabrication of Nd
conclusionsThe rationally designed Nd-RENPs nanoprobes manifest rapid-clearance property revealing the potential application toward the noninvasive preoperative imaging of tumor lesions and real-time intra-operative supervision.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.